NCT03610035View on ClinicalTrials.gov

A Study of NPT189 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 24, 2018

Primary Completion Date

February 17, 2019

Study Completion Date

February 17, 2019

Conditions
Amyloidosis
Interventions
DRUG

NPT189

IgG1 Fc-GAIM fusion protein, a recombinant fusion protein

DRUG

Placebo

Placebo

Trial Locations (1)

9728 NZ

PRA Health Sciences, Groningen

Sponsors
All Listed Sponsors
lead

Proclara Biosciences, Inc.

INDUSTRY